Medpace Holdings Inc vs Motorola Solutions Inc — how do they compare? Medpace Holdings Inc trades at $617.01 (market cap $16.82B), while Motorola Solutions Inc trades at $445.02 (market cap $74.00B). The key difference: Motorola Solutions Inc is far larger — about 4.4× Medpace Holdings Inc's market cap, and Motorola Solutions Inc pays a 1.08% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Motorola Solutions Inc for 100 Days on average.
| MEDP | MSI | |
|---|---|---|
Market Cap | $16.82B | $74.00B |
Volume | 223,093 | 722,147 |
Sector | Health | Technology |
52-Week High | $630.19 | $491.24 |
52-Week Low | $393.42 | $363.83 |
Typical Hold Time | 14 Days | 100 Days |
Enterprise Value | $16.44B | $82.90B |
Dividend Yield | — | 1.08% |
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
Motorola Solutions (MSI) trades at $443.80, down 1.04% on the day, with a bearish technical signal from moving averages. The company shows strong fundamentals with revenue growth to $11.68B in 2025 and net income of $2.15B, supported by a record $15.6B backlog as of Q2 2026 (Zacks Investment Research, 2026-09-28). Recent acquisitions like D-Fend Solutions for $1.5B expand its security portfolio, while a new $2B share repurchase authorization signals confidence (Business Wire, 2026-09-09).
The outlook is positive with a consensus price target of $525.86, implying 18.5% upside, and 71% of analysts rate it a Buy. Risks include elevated debt levels with a debt-to-asset ratio of 47.29% in 2025 and negative net cash flow trends, but strong public safety contract wins and AI integration in video analytics provide growth catalysts.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →Motorola Solutions, Inc. is a data communications and telecommunications equipment provider. The Company develops data capture, wireless, infrastructure, bar code scanning, two-way radios, and wireless broadband networks. Motorola also produces public safety and government products, voice and data communications products and systems, and wireless LAN securities.
Read more on MSI →